Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07260916

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation

MINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to either minimally invasive endoscopic SCUBA evacuation plus standard medical management or standard medical management alone; the time of randomization will be used to classify participants in one of two cohorts: 1) those randomized <8 hours from onset, and 2) those randomized 8-16 hours from onset. Randomization is targeted to occur within 120 min of arrival to the randomizing center's Emergency Department (ED), and initiation of surgery is targeted to occur within 120 min of randomization. Participants will be followed at 30, 90, 180, and 365 days to assess for adverse events (AEs) and utility-weighted modified Rankin Scale (UW-mRS).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 and ≤ 80 years
  • Non-traumatic, spontaneous, supratentorial, non-thalamic, BGH of volume ≥ 20 mL, as determined by the treating physician using ABC/2 method
  • NIHSS ≥ 6 at presentation
  • Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA) is performed and does not show an underlying vascular lesion
  • Pre-ICH mRS 0-2 Informed consent from patient or legally authorized representative (LAR) to participate in the trial, wherein patient/LAR's stated wishes are to pursue lifesaving therapies as opposed to early withdrawal of care (explicitly explained as <7 days following ictus)
  • The treating physician anticipates that surgery can be initiated <120 min from randomization
  • Randomization can occur ≤16 hours from LKW

Exclusion criteria

  • Suspected secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct Infratentorial or thalamic hemorrhage
  • Midbrain extension/involvement
  • Coagulopathy defined as international normalized ratio (INR) > 1.4
  • Elevated activated Partial Thromboplastin Time (aPTT) > 40 s
  • Concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset
  • Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency
  • Platelet count <100 x 103 cells/mm3, or known platelet dysfunction (reversal of coagulopathy is not allowed) GCS score <7 at presentation
  • Evidence of active infection indicated by fever ≥100.7 °F and/or open draining wound at the time of enrollment
  • Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 365 days
  • Intraventricular extension of the hemorrhage is visually estimated to involve > 50% of either of the lateral ventricles
  • Pregnancy (women of childbearing potential must have a negative pregnancy test to participate)
  • Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up schedule
  • Current participation in another interventional (drug or device) trial
  • Pre-existing Do Not Resuscitate (DNR)/Do Not Intubate (DNI) status
  • History of severe dementia

Treatment and study plan

Endoscopic ICH evacuation

Procedure

The intervention is minimally invasive endoscopic ICH evacuation using the SCUBA approach29. Stereotactic guidance must be used to guide placement of the sheath into the hematoma. Using stereotactic guidance software, a trajectory is planned along the long axis of the hematoma to the skull while avoiding eloquent brain regions, prominent vasculature, and other anatomy that should not be traversed during the approach, such as the frontal sinuses. A tele-proctor will be available to review the trajectory prior to the procedure starting. The procedure is performed under general anesthesia. The patient's head can be fixed if required depending on the stereotactic navigation system used.

Other names: SCUBA

Standard Medical Treatment

Other

Participating physicians will attest that they will manage all ICH patients in the medical and surgical arms of the trial according to their institutional standards of care, which they will attest are consistent with the American Stroke Association guidelines for management of spontaneous ICH66 and utilize a standardized blood pressure management and hydrocephalus management protocol.

Primary outcomes

  1. Utility-Weighted Modified Rankin Scale (UW-mRS)

    Time frame: Day 180

    Utility-Weighted Modified Rankin Scale (UW-mRS), a tool used primarily in stroke research to measure a patient's disability. It assigns a "utility" value (representing quality of life) to each level of the standard Modified Rankin Scale (mRS) to provide a more nuanced, patient-centered outcome measure than the mRS alone.

    The utility weighted mRS scales the 0-6 mRS range onto a 0-1 range, with higher scores indicating better health outcomes.

Secondary outcomes

  1. Number of successful endoscopic clot removal

    Time frame: during procedure

    Successful endoscopic clot removal to ≤10 mL remaining clot

  2. Volume of clot remaining post endoscopic clot removal

    Time frame: 24 hours post procedure

    Volume of clot remaining on follow-up 24-hour CT scan post endoscopic clot removal

  3. Number of post-procedural complications adverse events

    Time frame: up to 30 days

    Symptomatic rebleeding into the cavitary lesion after evacuation resulting in residual hematoma volume >10 mL and worsening of neurological status (defined as an increase in pre-evacuation NIHSS ≥4 points or a decrease in GCS ≥2 points which cannot be attributed to any other cause such as infection, seizures, sedation, or worsening edema) within 30 days.

  4. Number of CNS infection

    Time frame: Day 30

    CNS infection attributed to surgery

  5. Mortality (all-cause)

    Time frame: Day 30

    Number of mortalities, for any reason, at day 30

Study contacts

Contact information is provided by the study sponsor or research team.

Ally Qi, MPH

CONTACT

[email protected]

2093303024

Sukaina Davdani

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Collaborators

  • Beth Israel Deaconess Medical Center
  • Medical University of South Carolina
  • NINDS Stroke Trials Network (StrokeNet)
  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Official study title

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial

Acronym: MINUTE

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Dec 3, 2025
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.